{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087013","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.910763+00:00","generated_at":"2026-05-31T11:18:02.047943+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Century Therapeutics Q2 2024: Cash $269.6M, initiates Phase 1 SLE trial, advances CNTY-101","bullets":["Initiated Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, with protocol amended to include Lupus Nephritis cohort; expects initial data by year-end 2024.","Presented interim ELiPSE-1 trial data at ASCO showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas; dose escalation completed, dose expansion expected in 2H 2024.","Ended Q2 2024 with $269.6 million cash, equivalents, and investments; cash runway into 2026. GAAP operating expense guidance $150-$160 million.","Completed $60 million private placement and acquired Clade Therapeutics in April 2024, enhancing Allo-Evasion platform and adding preclinical αβ iT programs.","R&D expenses $27.2 million for Q2 2024 vs $22.7 million prior year; net loss $31.2 million vs $33.3 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087013","json":"https://secwatch.observer/filing/0001104659-24-087013.json","markdown":"https://secwatch.observer/filing/0001104659-24-087013.md","text":"https://secwatch.observer/filing/0001104659-24-087013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924087013/0001104659-24-087013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924087013/tm2421030d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:18:02.047943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}